DXA

BioAdaptives Announces Low-Cost AI FYO Smartphone App Tracking System to Detect Unwanted Muscle Mass Loss Reported With Obesity Management

Retrieved on: 
Thursday, February 1, 2024
Sarcopenia, Weight loss, Body composition, Research, Smartphone, AI, Obesity, MD, Safety, FYO, Childhood Obesity (journal), OTC, Facial muscles, Weakness, DXA, Dietary supplement

LAS VEGAS, NV, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, announces a new, Low-Cost AI FYO Smartphone App Tracking System to Detect Unwanted  Muscle Loss Reported with Obesity Management.

Key Points: 
  • LAS VEGAS, NV, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, announces a new, Low-Cost AI FYO Smartphone App Tracking System to Detect Unwanted  Muscle Loss Reported with Obesity Management.
  • Given that weight loss might stem from reductions in either body fat, muscle mass, or both, accurately measuring both components is crucial for monitoring the effectiveness and safety of obesity and fitness management strategies.
  • In contrast, Fit Your Outfit (FYO), a complimentary AI-powered smartphone app, offers immediate, cost-effective, personalized assessments of body fat and muscle mass, along with tracking capabilities that can support any obesity or fitness regimen.
  • The importance of tracking not only body fat but also muscle mass (fat free mass) has been highlighted by research that has identified the issue of unwanted muscle mass loss occurring with the use of some GLP-1 drugs and dieting practices.

BioAdaptives Announces Signing of a New Distributor’s Agreement for AI Body Composition Measuring App and New Weight Management System

Retrieved on: 
Wednesday, January 17, 2024
Facial muscles, Weight loss, Health, Diet, AI, DXA, FYO, Organization, FIT, Body composition, Medicine, Smartphone, Medical device

LAS VEGAS, NV, Jan. 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts:  BDPT) announced today the signing of a new non-exclusive Distributor’s Agreement directly with Pixelcando S.L.,Tenerife, Spain, owner and patent holder (US 10460450 B2 and WO 2016/189400 AI) of the innovative weight management system including the AI supported FIT YOUR OUTFIT (FYO) body composition smartphone App. This new, more comprehensive, Distributor’s Agreement with Pixelcando, supersedes the previously announced sub-dealer agreement with World Wellness. The new agreement authorizes Bioadaptive to market the AI supported FYO technology, in the US, both directly to retail individual clients, and also, B to B, to organizations such as weight management/nutritional and fitness companies, sports teams, Spas, health professionals and senior communities.

Key Points: 
  • This new, more comprehensive, Distributor’s Agreement with Pixelcando, supersedes the previously announced sub-dealer agreement with World Wellness.
  • FYO utilizes AI to scientifically measure body composition with a single photo from a smartphone with outstanding concordance and accuracy compared to the gold standard reference DXA.
  • It provides Advanced Body Composition Analysis: the App accurately measures factors such as body fat percentage, muscle mass, and water weight.
  • We are excited to participate in this global body composition analyzer and weight loss app market projected to grow to US$1.4 billion in 2027 and to US$2.6 billion by 2030, respectively.”

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

Retrieved on: 
Friday, January 12, 2024
Ageing, Patient, MHRA, Medication, MD, European Medicines Agency, Health care, Prednisone, Civil service commission, Dual-energy X-ray absorptiometry, European Commission, Steroid, Medicine, DXA, Spine, EMA, Mutation, Food, Safety, Vamorolone, FDA, Biomarker, DMD, Duchenne muscular dystrophy, Organic, Lead, Growth, Pharmaceutical industry

We are working towards making AGAMREE available to patients in the UK in the second half-year 2024, after NICE completes its pricing review.

Key Points: 
  • We are working towards making AGAMREE available to patients in the UK in the second half-year 2024, after NICE completes its pricing review.
  • Duchenne UK and our partner charities, Joining Jack and the Duchenne Research Fund, funded the early-stage clinical research to test vamorolone in patients, when no-one else would.
  • Santhera will continue to collect data to further characterize the long-term effectiveness and the broader safety differentiation of vamorolone.
  • This makes AGAMREE the first and only medicinal product fully approved in the EU and UK for DMD, and the first treatment approved for the treatment of DMD all three geographies.

Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Monday, December 18, 2023
Patient, Food, EMA, FDA, Catalyst Pharmaceuticals, European, Duchenne muscular dystrophy, Prednisone, Dual-energy X-ray absorptiometry, DXA, Mutation, Vamorolone, European Medicines Agency, Spine, DMD, Biomarker, Growth, Committee, Safety, Organization, Food and Drug Administration, CHMP, Pharmaceutical industry

In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.

Key Points: 
  • In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.
  • Santhera will continue to collect data to further characterize the long-term effectiveness and the broader safety differentiation of vamorolone.
  • Santhera announced on October 27, 2023 that the FDA approved AGAMREE oral suspension 40 mg/ml in the United States for the treatment of DMD in patients 2 years of age and older.
  • Catalyst Pharmaceuticals holds an exclusive license for AGAMREE in North America and plans to launch the product in the U.S. in Q1-2024.

BioAdaptives, Inc. Introduces PROTEINnMORETM Ahead of 2024 Launch of AI-based “Fit Your Outfit” app

Retrieved on: 
Thursday, December 14, 2023
Body composition, Marketing, GMO, FYO, Research, Nutrient, DXA, USD, Spirulina, OTC, Traditional Chinese medicine, Dietary supplement

LAS VEGAS, NV, Dec. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –BioAdaptives Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, announces the development of PROTEINnMORETM, an advanced, plant-based supplement designed to improve muscle growth and strength. Since Improving and maintaining lean muscle mass is an important goal in Fitness and Weight Management, BioAdaptives anticipates deployment of the previously announced AI-based Body Composition Measuring app, Fit Your Outfit, (FYO) during Q1 2024.

Key Points: 
  • Edward Jacobs, M.D., BioAdaptives CEO, stated, “PROTEINnMORETM is an all-natural, gluten-free, GMO-free supplement formulation designed to achieve and maintain top physical performance.
  • PROTEINnMORETM contains blended, purified hemp and pea protein combined with spirulina and other ingredients that naturally maximize gastrointestinal uptake and bioavailability of nutrients, including essential amino acids.
  • “In addition, this unique protein blend is formulated to promote muscle power by directly increasing contractility of muscle fibers.
  • PROTEINnMORETM provides a balanced blend of plant-based protein using all-natural ingredients that enhance blood flow and muscle function.

Affidea expands its presence in Europe with acquisitions in Spain and Romania

Retrieved on: 
Tuesday, December 5, 2023
Acquisition, Patient, Scan (company), Growth, MRI, DXA, Medical imaging, Nursing, Ultrasound, Mammography

Guy Blomfield, Chairman and CEO of Affidea Group, commented on this milestone, saying, "Affidea has significantly expanded its presence in 2023, completing a total of 14 acquisitions in eight countries, adding 25 new centres.

Key Points: 
  • Guy Blomfield, Chairman and CEO of Affidea Group, commented on this milestone, saying, "Affidea has significantly expanded its presence in 2023, completing a total of 14 acquisitions in eight countries, adding 25 new centres.
  • Today, we are thrilled to extend our presence in Spain and Romania, two markets with great potential.
  • With these acquisitions, Affidea reaches a team of 13.000 professionals across 15 countries, serving more than 13 million patients every year at the Group level.
  • These acquisitions represent a significant step forward for Affidea as the company continues to expand its presence across Europe, providing high-quality healthcare services that prioritise patient well-being.

Accomplished Marketing Leader Niki Hall Joins Five9 as Chief Marketing Officer

Retrieved on: 
Tuesday, October 24, 2023
Data Management, Technology, Marketing, Communications, Other Technology, Digital Marketing, Telecommunications, Software, Artificial Intelligence, Networks, VoIP, Cloud, Women in business, Woman, Research, Intelligence, CX, A Very Special Christmas: 25 Years Bringing Joy to the World, Organization, DXA, Cisco, AI, CMO, Automation, CCAA, Sales, Management, Poly

Five9 , (NASDAQ: FIVN) provider of the Intelligent CX Platform, announced today the appointment of Niki Hall, an industry leader with more than 20 years of experience in technology marketing, as chief marketing officer (CMO).

Key Points: 
  • Five9 , (NASDAQ: FIVN) provider of the Intelligent CX Platform, announced today the appointment of Niki Hall, an industry leader with more than 20 years of experience in technology marketing, as chief marketing officer (CMO).
  • Reporting directly to CEO Mike Burkland, Hall’s focus will be on all areas of B2B marketing, including demand generation, partner marketing, product marketing, field enablement, branding, corporate communications, analyst relations, channel marketing, marketing analytics, and events.
  • “Niki joins Five9 at an exciting time in our journey as we continue to expand globally,” said Mike Burkland, CEO, Five9.
  • Prior to Contentsquare, Niki was CMO at Selligent Marketing Cloud and held marketing leadership roles at Poly and Cisco.

Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on: 
Monday, October 16, 2023
Annual general meeting, Calcium, Hypoparathyroidism, McMaster University, Bone fracture, Bone disease, Society, American Society for Bone and Mineral Research, PTHR1, Homeostasis, Fracture, Phase 3, Osteoporosis, Medicine, DXA, Patient, PMF, Metabolic bone disease, Woman, Osteopenia, Quality of life, Medical imaging, Dietary supplement

LYON, France, and CAMBRDIGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced data from two posters that were presented at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023, in Vancouver, BC, Canada. The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF). In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.

Key Points: 
  • The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF).
  • In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.
  • “We’re very pleased to have a strong presence at this year’s ASBMR Annual Meeting.
  • These data increase our understanding of the relationship between hypoparathyroidism and bone strength.

Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Friday, October 13, 2023
European, Quality of life, Biomarker, CHMP, Lead, DMD, European Commission, Safety, European Medicines Agency, Spine, Disease, Vamorolone, EMA, Dual-energy X-ray absorptiometry, FDA, Steroid, LR, Ludwig Maximilian University of Munich, Prednisone, NDA, EC, Growth, Neurology, DXA, Catalyst Pharmaceuticals, Associate, Patient, MA, Civil service commission, PDUFA, Pharmaceutical industry, Medical device, Medical imaging, Becker, MD, Duchenne, EU

Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.

Key Points: 
  • Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.
  • “We are thrilled about the CHMP’s positive opinion, which recognizes the urgent medical need for an effective and well tolerated treatment for this devastating disease.
  • “We are very excited about the positive opinion from the European Medicines Agency,” declared Ezio Magnano, President of Parent Project Italy.
  • A marketing authorization decision from the EC is expected within approximately two months of the positive CHMP opinion.

WalkMe Named A Leader and A Star Performer in Everest Group Digital Adoption Platform PEAK Matrix® Assessment 2023 for Fourth Consecutive Year

Retrieved on: 
Thursday, September 28, 2023
WalkMe, Communication, UI, Dentsu, The X Factor Digital Experience, Research, Element, Jelly shoes, DIY, Vision, Digital adoption platform, Organization, DXA, Work, SAN, Map, AI, HTML, ROI, DAP, Software, Customer service, Retail

SAN FRANCISCO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Continuing its market leadership as the pioneers of the Digital Adoption Platform (DAP) category, WalkMe Ltd .

Key Points: 
  • SAN FRANCISCO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Continuing its market leadership as the pioneers of the Digital Adoption Platform (DAP) category, WalkMe Ltd .
  • (NASDAQ: WKME) today announced it has been named a Leader and a Star Performer in the Everest Group Digital Adoption Platform Products PEAK Matrix® assessment 2023.
  • This distinction marks the fourth consecutive year WalkMe secured placement in the top category, capturing the highest marks in both Market Impact and Vision & Capability with the highest overall scores.
  • With 24 patents granted and another 28 pending, WalkMe’s relentless commitment to innovation is shaping the future of work.